Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: An observational cohort study

Annals of Surgery

Volumn 256, Issue 6, 2012, Pages 1078-1083

  Cashin, Peter H ^a   Graf, Wilhelm ^a   Nygren, Peter ^b   Mahteme, Haile ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

colorectal cancer; corep score; cytoreductive surgery; HIPEC; hyperthermic intraperitoneal chemotherapy; patient selection; peritoneal carcinomatosis; peritoneal metastases; serum tumour markers

Indexed keywords

ANTINEOPLASTIC AGENT; SERUM TUMOR MARKER; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; COLORECTAL PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MALE; OBSERVATIONAL STUDY; PATIENT SELECTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; CARCINOMA; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PATIENT SELECTION; PERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870055965     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318254f281     Document Type: Article

References (36)

1. Moran B, Baratti D, Yan TD, et al. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98:277-282.
2. Deraco M, Bartlett D, Kusamura S, et al. Consensus statement on peritoneal mesothelioma. J Surg Oncol. 2008;98:268-272.
3. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyper-thermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128-133.
4. Esquivel J, Elias D, Baratti D, et al. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98:263-267.
5. Gilly FN. Phase II studies: international registry of colorectal carcinomatosis. Eur J Surg Oncol. 2006;32:648-654.
6. Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg. 2008;248:829-835.
7. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperi-toneal hyperthermic chemotherapy with mitomycin C for peritoneal car-cinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178-186.
8. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43:1341-1346.
9. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-3292.
10. Bretcha-Boix P, Farré-Alegre J, Sureda M, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcino-matosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies. Clin Transl Oncol. 2010;12:437-442.
11. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979-984.
12. Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreduc-tive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896-901.
13. Cavaliere F, De Simone M, Virz̀i S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37:148-154.
14. Hansson J, Graf W, Påhlman L, et al. Postoperative adverse events and longterm survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2009;35:202-208.
15. Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403-407.
16. de Bree E, Koops W, Kröge r R, et al. Peritoneal carcinomatosis from colorec-tal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86:64-73.
17. Jacquet P, Jelinek JS, Steves MA, et al. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72:1631-1636.
18. Suzuki A, Kawano T, Takahashi N, et al. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging. 2004;31:1413-1420.
19. Tempany CM, Zou KH, Silverman SG, et al. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215:761-767.
20. Yan TD, Sim J, Morris DL. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:1807-1817.
21. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus in-traperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomato-sis of colorectal origin. J Clin Oncol. 2009;27:681-685.
22. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcino-matosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330-1336.
23. Laterza B, Kusamura S, Baratti D, et al. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic in-traperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23:187-190.
24. Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739-746.
25. de Bree E, Koops W, Kröger R, et al. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2006;32:65-71.
26. Lee SD, Park JW, Park KS, et al. Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis. 2009;24:1451-1458.
27. Tampellini M, Saini A, Alabiso I, et al. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br J Cancer. 2006;95:13-20.
28. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
29. Massacesi C, Rocchi MBL, Marcucci F, et al. Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. Int J Biol Markers. 2003;18:295-300.
30. Webb A, Scott-Mackie P, Cunningham D, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohisto-chemistry in advanced colorectal cancer. Ann Oncol. 1995;6:581-587.
31. Kouri M, Pyrhönen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol. 1992;49:78-85.
32. Wang W-S, Lin J-K, Chiou T-J, et al. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 2002;49:160-164.
33. Guadagni F, Roselli M, Cosimelli M, et al. CA 72-4 serum marker-a new tool in the management of carcinoma patients. Cancer Invest. 1995;13:227-238.
34. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.
35. Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565-570.
36. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608-5618.